The firm's consumer-initiated testing business grew year over year by more than 20 percent in 2025, generating roughly $250 million in revenue.

NEW YORK – Following the completion of Waters' acquisition of Becton Dickinson's biosciences and diagnostics business, investment bank Barclays said on Tuesday that it has reinstated coverage of ...

Under the agreement, Labcorp will become the clinically integrated laboratory provider of choice for all SOMOS providers, care teams, and patients.

Calbiotech will combine its assay development, manufacturing, and distribution capabilities with Liquid Biosciences' biomarker discovery and clinical innovation platform.

Revenue for the quarter was $2.81 billion, up from $2.62 billion in the same quarter last year and above the consensus Wall Street estimate of $2.76 billion.

Last week, readers were most interested in a story about the growing use of blood-based tests for patients who may have Alzheimer's but show no symptoms.

While still in an early stage, interest in testing asymptomatic patients is growing as drug developers explore treating ...

The award is the first following a funding announcement last year to support typhoid fever diagnostic test development.

Under the deal, Sysmex will exclusively sell Fujirebio's Lumipulse immunoassay systems and dementia-related tests in certain geographies.

The survey of 152 clinicians also found that turnaround time and payor coverage are among the most important considerations for doctors when ordering cancer testing.

The platform uses impedance flow cytometry to measure the electrical properties of bacteria that have been plated from a positive blood culture sample.

The panel is for use with Randox's Evidence MultiSTAT analyzer, which is also FDA cleared, and provides the simultaneous detection of 15 drugs of abuse — including methamphetamine, fentanyl, marijuana ...